ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood products, ...

Scientists have long been racking their brains for ways to treat Alzheimer’s disease, the most common type of dementia. Turns out that the answer may lie within our own brains. Researchers from ...

In an unprecedented large-scale study, researchers have mapped out the first molecular events that cause harmful protein buildups in the brain of people with Alzheimer's disease. "By measuring the ...

More than half of 95 centenarians had a low amyloid load and 9% had no amyloid, autopsy data showed. A third of centenarians had a high amyloid load comparable to Alzheimer's disease. Five ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the midstage study has been tied to one death. The interim data come from ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can delay the ...

Piller is an investigative journalist for Science. In November 2022, Dennis Selkoe, a Harvard professor of neurologic diseases and among the most celebrated and prolific Alzheimer’s researchers, ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive neurodegenerative disease that is characterized by cognitive decline. Given ...

A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab helps ...